Background: Sodium-glucose transporter-2 inhibitor (SGLT2) is reported to have anti-atherosclerotic effects in experiment. However, the effect of SGLT2 on endothelial function (ECF) in humans is not fully investigated. Method and Results: We measured ECF in 11 diabetic patients with coronary artery disease (CAD) and poor control of diabetics (HbA1c >7%; 75 8 years old) by simultaneously measuring brachial artery flow-mediated dilation (FMD) and EndoPAT2000 (measuring RHI). FMD and RHI were measured before and after mean periods of 4-week treatment of Canagliflozin (100 mg per every other day). Canagliflozin improved HbA1c along with increasing FMD and RHI (HbA1c, 9.2 1.4 vs. 8.6 1.1%, P<0.01; FMD, 6.40 1.29 vs. 8.98 1.68%, P<0.01; RHI, 1.5 0.3 vs.1.8 0.3, P<0.05). In addition, the changes of HbA1c did not tend to correlate with either FMD or RHI. Conclusions: Since the improved FMD and RHI reflect salutary effect of Canagliflozin on ECF, these results might suggest that SGLT2 could have anti-arteriosclerotic effects in diabetics with CAD.
Introduction
Diabetes mellitus (DM) has been increased in our country and the cardiovascular complication such as ischemic heart disease, stroke and chronic kidney diseases have become one of the leading causes to untoward outcomes of diabetic patients 1) . Recently, new class oral hypoglycemic medication of sodium-glucose transporter-2 inhibitor (SGLT2) has been reported to improve the prognosis in patients with type 2 DM 2) . SGLT2 could more effectively prevent target organ damage in diabetic patients 3) than the conventional oral hypoglycemic agents, and this effect is tended to be independent of its blood sugar lowering effect 2) . In addition, SGLT2 therapy might be able to attenuate the atherosclerotic effect of DM in humans 4) because the several experimental studies evaluating SGLT2's anti-atherosclerotic effects showed the significant salutary results of SGLT2 for anti-atherosclerosis in the animal model or the in-vitro tests 5) . Among these studies, the mechanism of SGLT2 effects on antiatherosclerosis could be due to anti-oxidative effect and preserving effect on the nitric oxide metabolism 6) . Flow-mediated dilation (FMD) and EndoPAT2000 (measuring reactive hyperemic index [RHI] by tonometry method) in the brachial artery are well known indices for evaluating endothelial function (ECF) 7) . However, the effect of SGLT2 on ECF in humans has not been fully understood.
Thus, the purpose of this study was to investigate the effect of the SGLT2 therapy on endothelial function, as assessed by brachial artery FMD and RHI in the patients with type 2 DM complicated with possible coronary heart disease (CAD).
Methods

Study population and protocol
The study population consisted of 11 patients (9 men and 2 women; age, 74.7 7.2 years) who have visited our outpatient clinic of cardiology department in National Defense Medical College hospital under the diagnosis of CAD with type 2 DM. Since the ECF tests of FMD and RHI have been approved by the public insurance in Japan and the management guideline determined by the Japanese Circulation Society has recommended and approved these tests for the patient care 8) , these tests have been performed in the routine evaluation for the current status or the risk stratification of the patients with CAD in our hospital. Among the total 34 patients with CAD and type 2 DM who had been prescribed SGLT2 medicine at the time periods from January 2016 to December 2017, we retrospectively selected 11 patients who eventually received ECF tests of FMD and RHI before and after adding SGLT2 treatment of Canagliflozin (100 mg per every other day for 4-week periods). All tests were performed by the patient's requests or the decision of the doctor in charge by considering necessity of evaluation for ECF tests because of the existence of multiple coronary risk factors and/or the poorly controlled DM, in order to get the clues for preventing the onset of acute coronary syndrome. In addition, secondary hypertension such as primary aldosteronism and the patients with either renal artery stenosis or chronic renal failure had been worked out and excluded from the selection for study population. Additional exclusion criteria were as follows: 1) allergic reaction to SGLT2; 2) the presence of diabetic acidosis; 3) advanced heart block; 4) uncompensated congestive heart failure; 5) any malignant disorders; 6) any other acute disorders; or 7) severe hypertensive patients who experienced hypertensive crisis. Informed consent was obtained from each patient. To use the patient's any information for this study, written informed consent was obtained from each patient and this clinical study was approved by institutional review board.
Physical examination and blood tests in the routine outpatient visit Blood pressure (BP), heart rate (HR) and body weight measurement BP measurements were followed by the guideline of American Heart Association Scientific Statement 9) . The patients were asked to take away all clothing that covered the position of the cuff placement. And they were comfortably seated and the cuff on the upper arm was placed at the level of right atrium. The patients were instructed to relax, and at least 5 min passed before the BP measurement was carried out. All study patients had systolic BP !140 mmHg and/or diastolic BP !90 mmHg when BP was obtained in the sitting position at outpatient clinics. BP was measured by Korotkoff's method using a sphygmomanometer. HR was directly obtained by stethoscope attached on the precordial region of the chest wall. Body weight was also measured in every visit at outpatient clinic.
Blood sample tests
Venous blood was obtained. Blood samples were tested for routine blood chemistry including liver and renal function tests, lipid profile, fasting blood sugar (FBS), HbA1c and complete blood counts, according to standard methods. All of these measurements were repeated before and after SGLT2 treatment as performed in the routine patient care.
Ultrasound FMD and RHI measurements in the brachial artery
All ultrasound studies were done in a temperaturecontrolled room (25 degree centigrade [°C] ) with the subject in a fasting, resting, and supine state from approximately 14:00 to 17:00. Heavy meals, including a high fat diet and caffeine-containing beverages, were prohibited beginning the night before the study. Patients were not allowed to have lunch on the day of ultrasound study. BP and HR were recorded from the left arm every 3 min with an automatic sphygmomanometer (Nihon Korin, BP-203, Tokyo, Japan) during the ultrasound procedure. Vasodilatation responses of the brachial artery were determined by the ultrasound technique using a semi-automatic device (EF18G; UNEX, Nagoya, Japan). Briefly, the diameter of the brachial artery was measured from B-mode ultrasound images using a 10-MHz linear array transducer. Then, a BP cuff was inflated to 50 mmHg above the systolic BP over the proximal portion of the right forearm for 5 min. The diastolic diameter of the brachial artery was determined semi-automatically using an instrument equipped with software for monitoring the brachial artery diameter. The changes in the diastolic diameter were continuously recorded. Then, FMD was determined as the maximum change in diameter after cuff release normalized to the baseline diameter (% of baseline diameter). Calculation of these values by the EF18G in our laboratory showed that both the intra-and inter-observer variability (coefficient of variation) for repeated measures of diameter before and after reactive hyperemia in the brachial artery were < 3% 10, 11) . Assessment of endothelial function by reactive hyperemia peripheral arterial tonometry (RHI measure) was simultaneously assessed by reactive hyperemia peripheral arterial tonometry using the EndoPAT2000 system (Itamar Medical, Caesarea, Israel) with FMD. As described previously 12) , RHI was automatically calculated, and there is minimal interoperator and intraoperator variability. Since FMD and RHI was measured simultaneously, RHI studies were performed when patients were in stable as described above. The RHI value that reflected the extent of reactive hyperemia was calculated as the ratio of the average pulse amplitude of EndoPAT2000 system signal over a 1-minute time interval starting 1.5 min after cuff deflation to the average pulse amplitude of EndoPAT2000 system signal of the 2.5-minute time period before cuff inflation (baseline). The RHI value was calculated by the EndoPAT2000 system. As mentioned earlier, previous studies have demonstrated that RHI has excellent reproducibility 12, 13) .
Statistical Analysis
Data are expressed as the mean SD. Even if the sample size was small, the histogram of each sample were not skewed (data not shown) so that we presumed each samples in this study were drawn from normally distributed data. 
Results
Patient Profile
The present study population consisted of 11 patients and the prevalence of complications or comorbid conditions, and combination treatments are shown in Table 1 , 2. Clinical characteristic in each patient is listed in Table 1 and summarized characteristics are shown in Table 2 . Mean age in study group was approximately 75 years (elderly populations). All patients had a clinically diagnosed CAD. Approximately 91% of patients had hypertension, 100% hypercholesterolemia, and 27% had hyperuricemia. Combination medical treatment is also described in Table 2 . As shown in the Table 2 , as being consistent with the high prevalence of atherosclerotic risk factors in this study population, 100% of patients have taken anti-platelet agents, 82% angiotensin II receptor blocker, 73% β blocker, 100% statin treatment, and 27% patients had nitrates and calcium channel blocker therapy. In addition, about half of the patients were treated by oral hypoglycemic agents, and 73% patients were prescribed dipeptidyl peptidase-4 inhibitor (DPP4). No insulin therapy was found.
Changes in BP, HR and body weight
As shown in Table 3 , the 4-week treatment of Canagliflozin significantly decreased the body weight whereas Canagliflozin did not influence the systemic hemodynamics expressed by the changes in BP and HR.
Changes in blood sample tests
As shown in Table 4 , Figure 1 and Figure 2 , the 4-week treatment of Canagliflozin significantly decreased both FBS and HbA1c. In addition, Canagliflozin treatment significantly improved liver function indices such as serum alanine aminotransferase (s-ALT), lactate dehydrogenase (LDH), and gamma-glutamyl transpeptidase (rGTP) values. 
Changes in FMD and RHI
The effects of Canagliflozin treatment on FMD and RHI are summarized in Table 3 . As shown in Table 3 and Figure 3, 4 , the 4-week treatment of Canagliflozin caused a significant increase in FMD and RHI. No significant changes were found in baseline brachial artery diameter. By Canagliflozin treatment, the change in HbA1c in response to treatment did not significantly correlate with changes in either FMD or RHI (delta HbA1c vs. delta FMD, r= -0.19, n= 11, NS; delta HbA1c vs. delta RHI, r= -0.43, n=11, NS).
Discussion
The present study demonstrated that SGLT2 therapy has salutary effect on endothelial function assessed by brachial artery FMD and RHI in the patients with type 2 DM complicated with possible CAD, possibly independent with the control of blood sugar. In our study population, almost all patients had definite or possible CAD complication with the multiple coronary risk factors. In addition, all patients received almost full medications for the secondary prevention of acute coronary syndrome as shown in Table 1 . Despites having multiple coronary risk factors with CAD and the poor control of blood sugar as DM, ECF at the baseline was relatively well preserved as shown Table 2 , 3 as well as Figure 3, 4 . The mean values of FMD and RHI were 6.40% and 1.5, respectively, possible due to above full preventive medication. These medications were reported to im- prove ECF assessed by either FMD or RHI 14) . Even if the relatively preserved ECF, the half dose of adding Canagliflozin of SGLT2 further increased both FMD and RHI values, suggesting the improvement of brachial artery ECF. Along with the improvement of ECF, Canagliflozin decreased fasting blood sugar (FBS) and HbA1c levels as shown in Table 3 . The changes in ECF did not significantly correlate with those of the changes in FBS and HbA1c. The beneficial effect of Canagliflozin on ECF might be independent with the blood sugar controls in the present study population.
The precise mechanisms of healthful efficacy of Canagliflozin of SGLT2 could not be clarified by this study, and the speculated mechanisms are either due to the improving effect on nitric oxide metabolism by anti-oxidant action of SGLT2 and/or the synergic property of DPP4 and SGLT2 on anti-atherosclerotic function 15) . In the experimental animal studies, SGLT2 showed anti-atherosclerotic effects through anti-oxidant effects 6) . Further, SGLT2 and DPP4 showed synergic effects on the anti-atherosclerotic effect in the experimental study 16, 17) , and the preliminary clinical study [18] [19] [20] .
Intestinal sodium glucose cotransporter-1 inhibition was reported to enhance glucagon-like peptide-1 (GLP-1) secretion in normal and diabetic rodents 21) . Especially, Canagliflozin was reported to potentiate GLP-1 secretion and lower the peak of GLP -1 secretion in DM rats 22, 23) . The effect of combined treatment with Canagliflozin and teneligliptin could be more useful than either DPP4 or SGLT2 therapy alone. In this study, more than 70% of study patients already prescribed DPP4 before the beginning of SGLT2 treatment. The synergic effect of DPP4 and SGLT2 possible could further improve ECF in the present study.
In addition, the present study results agree with the previously reported findings 24, 25) . Since SGLT2 are relatively new oral hypoglycemic agents on the clinical settings, there are few studies on the effect of SGLT2 and the synergic effect of DPP4 and SGLT2 in humans. In the real world, SGLT2 is frequently added to DM patients similar to this study 20) . And preliminary clinical study showed that the combination therapies of DPP4 and SGLT2 seem to be effective in the treatment of patients with type 2 DM 19, 20) . These findings are similar to our results. However, they are all preliminary study, and large scale clinical studies are now already planned 26, 27) . We need to see further results of these studies to get the final answer to our hypothesis.
Another findings in our study suggested that SGLT2 might ameliorate liver dysfunction caused by fatty liver that has frequently been seen in metabolic syndrome. As shown in Table 4 , Canagliflozin prescription significantly decreased s-ALT, LDH, and rGTP. Further, s-AST tended to be decreased by Canagliflozin medication. There are several previous studies showing that SGLT2 improved liver function due to non-alcoholic fatty liver complicated with type 2 diabetics [28] [29] [30] . However, the effect of Canagliflozin on liver function is out of our scope of this study and the definite answer remains for further future research.
Study Limitations
First, this study is cross sectional retrospective single center study and the numbers of study patients are small so that the power of the study is limited. As mentioned above, in order to confirm our results and speculation, the results of currently ongoing randomized multi-center clinical 26, 27) should be obtained and reviewed. Second, we performed ECF tests using simultaneous measures of FMD and RHI. However, we did not measure nitroglycerin-mediated dilation (NMD), which is independent measure of ECF. To precisely measure ECF by FMD method, NMD should be measured. In general, when preserved ECF is found by FMD technique, NMD, that is the reflection of vascular smooth muscle function, is well preserved so that NMD is presumed to be considered normal in the present study patients. The NMD measurement could be reasonably omitted in the current study. Third, Canagliflozin treatment did not make the significant correlation between the change in HbA 1c and those of either FMD or RHI. These results could be caused by type II errors due to the small number of study population. The conclusion on this finding should be also preserved until the results of currently ongoing randomized multi-center clinical will be obtained 26, 27) . Fourth, in the previous reports 8, 12) , RHI was measured by using upper arm cuff occlusion method. However, in the present study, we measured RHI by forearm occlusion method because of simultaneous measurements of FMD and RHI. The influence of the occlusion site on the results of this study could not be ruled out. The further investigation is necessary to clarify this important issue.
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